anti-cd74: a b-cell receptor of interest

[Guest guest]

Clinical Trials: http://clinicaltrials.gov/ct2/results?term=anti-CD74

Immunomedics Awarded U.S. Patent for Internalizing Anti-CD74 Antibodies and

Methods... Tue Jan 8, 2008 8:31am EST

MORRIS PLAINS, N.J., Jan. 8, 2008 (PRIME NEWSWIRE) -- Immunomedics, Inc.

(Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal

antibodies to treat cancer and other serious diseases, today announced that

its patent application for " Internalizing anti-CD74 antibodies and methods

of use " has been issued as U.S. patent no. 7,312,318.

The patent covers the composition of matter for humanized, chimeric and

human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates,

vaccines and bispecific antibodies that bind to CD74, the major

histocompatibility complex (MHC) class-II invariant chain, Ii, which is

potentially useful for the treatment and diagnosis of B-cell disorders,

such as B-cell malignancies, other malignancies in which the cells are

reactive with CD74, and autoimmune diseases, and methods of treatment and

diagnosis.

The Company's lead anti-CD74 product candidate, milatuzumab, is a humanized

antibody currently in Phase I/II studies for patients with multiple myeloma

who have failed at least two prior standard systemic anti-myeloma treatment

regimens. In addition, P Leonard, MD, Weill Cornell Medical, is

conducting a Phase I, open-label study in patients with recurrent

non-Hodgkin's lymphoma or chronic lymphocytic leukemia

full text:

http://www.reuters.com:80/article/pressRelease/idUS137854+08-Jan-2008+PNW2008010\

8